Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jun 1, 2018
Clinical News

Gilead's Epclusa approved in China for HCV

BioCentury | May 30, 2018
Company News

Gilead's Epclusa approved in China for HCV

BioCentury | Sep 29, 2017
Clinical News

China approves HCV drugs from Gilead and AbbVie

BioCentury | Sep 29, 2017
Clinical News

Merck discontinues HCV candidates

BioCentury | Sep 26, 2017
Company News

GSK, Gilead, Shire gain RDPAC membership

BioCentury | Sep 25, 2017
Company News

Gilead's Sovaldi gets Chinese approval

BioCentury | Sep 15, 2017
Company News

J&J drops Achillion HCV deal

Items per page:
1 - 10 of 676